StockNews.com began coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

Search for the best digital art software and the best drawing software and you'll find plenty of options, all offering a broad array of brushes, design tools, and sharing possibilities to get your ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The FDA has cleared Spineart’s Perla TL application for use with eCential Robotics Op.nTM robotic navigation platform. The clearance will combine Spineart and eCential Robotics’ robotic-assisted spine ...

Nevro Corp是一家全球医疗器械公司，专注于提供继续为慢性疼痛治疗持久患者结果设定标准的全面的、改变生活的解决方案。该公司开发并商业化Senza脊髓刺激（SCS）系统。SCS是一个用于治疗慢性疼痛的神经调节平台，除了Senza系列产品之外，还包括Senza Omnia平台 ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...